Published in Cancer Weekly, May 1st, 2006
"Although completion lymph node dissection (CLND) is the standard of care for breast cancer patients with SLN metastases, the SLN is the only node with tumor in 40% to 60% of cases. To assist with decision-making regarding CLND, investigators at Memorial Sloan-Kettering Cancer Center devised and validated a nomogram for predicting the likelihood of non-SLN metastases," scientists in the United States reported.
"To assess the generalizable use of this nomogram, validation analysis was performed by using an external...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.